{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:50:14Z","timestamp":1793998214281,"version":"4.8.0"},"reference-count":81,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Dermatitis\u00ae"],"published-print":{"date-parts":[[2022,2,1]]},"abstract":"<jats:p>There is overwhelming evidence that many delayed cutaneous adverse drug reactions (beginning &gt;6 hours after drug intake) are mediated by delayed-type (type IV) hypersensitivity, including maculopapular eruptions, erythroderma, symmetrical drug-related intertriginous and flexural exanthema\/baboon syndrome, eczematous eruptions, fixed drug eruptions, acute generalized exanthematous pustulosis, and drug reaction with eosinophilia and systemic symptoms\/drug-induced hypersensitivity syndrome. Therefore, after resolution of the reaction, patch tests should be performed as first diagnostic method to identify the culprit drug(s). This article provides tools to perform drug patch tests properly and safely, discussing clinical history, indications, procedure, drug patch test materials, sensitivity, the meaning of negative patch tests, and safety of the procedure. In addition, a literature review of eruptions and culprit drugs is provided in tabular format.<\/jats:p>","DOI":"10.1097\/der.0000000000000839","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T14:35:55Z","timestamp":1642084555000},"page":"16-30","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":19,"title":["Patch Testing in Drug Eruptions: Practical Aspects and Literature Review of Eruptions and Culprit Drugs"],"prefix":"10.1177","volume":"33","author":[{"given":"Anton C.","family":"de Groot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,2,1]]},"reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.12350"},{"key":"e_1_3_1_3_2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/all.13562","article-title":"EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity","volume":"74","author":"Brockow K","year":"2019","unstructured":"Brockow K, , Ardern-Jones MR, , Mockenhaupt M, et al. EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity. Allergy, 2019; 74:14\u201327.","journal-title":"Allergy"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.12142"},{"key":"e_1_3_1_5_2","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1016\/j.jaip.2020.07.005","article-title":"Delabeling delayed drug hypersensitivity: how far can you safely go?","volume":"8","author":"Lehloenya RJ","year":"2020","unstructured":"Lehloenya RJ, , Peter JG, , Copascu A, et al. Delabeling delayed drug hypersensitivity: how far can you safely go?. J Allergy Clin Immunol Pract, 2020; 8:2878\u20132895.e6.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"e_1_3_1_6_2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaci.2018.10.030","article-title":"Controversies in drug allergy: testing for delayed reactions","volume":"143","author":"Phillips EJ","year":"2019","unstructured":"Phillips EJ, , Bigliardi P, , Bircher AJ, et al. Controversies in drug allergy: testing for delayed reactions. J Allergy Clin Immunol, 2019; 143:66\u201373.","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_3_1_7_2","doi-asserted-by":"crossref","DOI":"10.1201\/9781003158004","volume-title":"Monographs in Contact Allergy, Volume 4: Systemic Drugs","author":"De Groot AC","year":"2022","unstructured":"De Groot AC. Monographs in Contact Allergy, Volume 4: Systemic Drugs. Boca Raton, FL: CRC Press Taylor and Francis Group; 2022. ISBN 978-0-367-43649-0."},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-014-0442-8"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1996.tb02364.x"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12125"},{"key":"e_1_3_1_11_2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-0536.2009.01659.x","article-title":"Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS)","volume":"62","author":"Santiago F","year":"2010","unstructured":"Santiago F, , Gon\u00e7alo M, , Vieira R, et al. Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS). Contact Dermatitis, 2010; 62:47\u201353.","journal-title":"Contact Dermatitis"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04418.x"},{"key":"e_1_3_1_13_2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/ced.12239","article-title":"Utility of patch testing for patients with drug eruption","volume":"39","author":"Ohtoshi S","year":"2014","unstructured":"Ohtoshi S, , Kitami Y, , Sueki H, et al. Utility of patch testing for patients with drug eruption. Clin Exp Dermatol, 2014; 39:279\u2013283.","journal-title":"Clin Exp Dermatol"},{"key":"e_1_3_1_14_2","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1600-0536.2009.01578.x","article-title":"Usefulness of skin testing in cutaneous drug eruptions in routine practice","volume":"61","author":"Tchen T","year":"2009","unstructured":"Tchen T, , Reguia\u00ef Z, , Vitry F, et al. Usefulness of skin testing in cutaneous drug eruptions in routine practice. Contact Dermatitis, 2009; 61:138\u2013144.","journal-title":"Contact Dermatitis"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02313.x"},{"key":"e_1_3_1_16_2","first-page":"47","article-title":"Tests cutan\u00e9s dans l'exploration des toxidermies suppos\u00e9es de m\u00e9canisme immuno-allergique [in French]","volume":"184","author":"Barbaud A","year":"2000","unstructured":"Barbaud A, , Bene MC, , Faure G, et al. Tests cutan\u00e9s dans l'exploration des toxidermies suppos\u00e9es de m\u00e9canisme immuno-allergique [in French]. Bull Acad Natl Med, 2000; 184:47\u201363.","journal-title":"Bull Acad Natl Med"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.1990.tb01631.x"},{"key":"e_1_3_1_18_2","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/ACI.0000000000000548","article-title":"Cutaneous drug hypersensitivity: developments and controversies","volume":"19","author":"Brockow K","year":"2019","unstructured":"Brockow K, , Pf\u00fctzner W. Cutaneous drug hypersensitivity: developments and controversies. Curr Opin Allergy Clin Immunol, 2019; 19:308\u2013318.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"e_1_3_1_19_2","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.2174\/1381612825666191107104126","article-title":"Role of in vivo and in vitro tests in the diagnosis of severe cutaneous adverse reactions (SCAR) to drug","volume":"25","author":"Bergmann MM","year":"2019","unstructured":"Bergmann MM, , Caubet JC. Role of in vivo and in vitro tests in the diagnosis of severe cutaneous adverse reactions (SCAR) to drug. Curr Pharm Des, 2019; 25:3872\u20133880.","journal-title":"Curr Pharm Des"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000546"},{"key":"e_1_3_1_21_2","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/ddg.13362","article-title":"Delayed-type hypersensitivity to oral and parenteral drugs","volume":"15","author":"Brandt O","year":"2017","unstructured":"Brandt O, , Bircher AJ. Delayed-type hypersensitivity to oral and parenteral drugs. J Dtsch Dermatol Ges, 2017; 15:1111\u20131132.","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_3_1_22_2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/ACI.0b013e32833aa54d","article-title":"Patch testing in drug allergy","volume":"10","author":"Friedmann PS","year":"2010","unstructured":"Friedmann PS, , Ardern-Jones M. Patch testing in drug allergy. Curr Opin Allergy Clin Immunol, 2010; 10:291\u2013296.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"e_1_3_1_23_2","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.iac.2009.04.010","article-title":"Skin testing in delayed reactions to drugs","volume":"29","author":"Barbaud A","year":"2009","unstructured":"Barbaud A. Skin testing in delayed reactions to drugs. Immunol Allergy Clin N Am, 2009; 29:517\u2013535.","journal-title":"Immunol Allergy Clin N Am"},{"key":"e_1_3_1_24_2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1710-1492-4-2-66","article-title":"Patch testing in non-immediate drug eruptions","volume":"4","author":"Romano A","year":"2008","unstructured":"Romano A, , Viola M, , Gaeta F, et al. Patch testing in non-immediate drug eruptions. Allergy, Asthma Clin Immunol, 2008; 4:66\u201374.","journal-title":"Allergy, Asthma Clin Immunol"},{"key":"e_1_3_1_25_2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1586\/17469872.2.4.481","article-title":"Drug skin tests and systemic drug reactions: an update","volume":"2","author":"Barbaud A","year":"2007","unstructured":"Barbaud A. Drug skin tests and systemic drug reactions: an update. Expert Rev Dermatol, 2007; 2:481\u2013495.","journal-title":"Expert Rev Dermatol"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282f7cb60"},{"key":"e_1_3_1_27_2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fmed.2020.00156","article-title":"Intradermal tests with drugs: an approach to standardization","volume":"7","author":"Barbaud A","year":"2020","unstructured":"Barbaud A, , Weinborn M, , Garvey L, et al. Intradermal tests with drugs: an approach to standardization. Front Med (Lausanne), 2020; 7:156.","journal-title":"Front Med (Lausanne)"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2003.00279.x"},{"key":"e_1_3_1_29_2","first-page":"999","article-title":"Drug hypersensitivity: questionnaire","volume":"54","author":"Demoly P","year":"1999","unstructured":"Demoly P, , Kropf R, , Bircher A, et al. Drug hypersensitivity: questionnaire. EAACI interest group on drug hypersensitivity. Allergy, 1999; 54:999\u20131003.","journal-title":"EAACI interest group on drug hypersensitivity. Allergy"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/cod.12432"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.13956"},{"key":"e_1_3_1_32_2","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/ddg.13971","article-title":"S3 Guidelines: epicutaneous patch testing with contact allergens and drugs\u2014short version, part 2","volume":"17","author":"Mahler V","year":"2019","unstructured":"Mahler V, , Nast A, , Bauer A, et al. S3 Guidelines: epicutaneous patch testing with contact allergens and drugs\u2014short version, part 2. J Dtsch Dermatol Ges, 2019; 17:1187\u20131207.","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_3_1_33_2","first-page":"1019","volume-title":"Contact Dermatitis","author":"Goossens A","year":"2020","unstructured":"Goossens A, , Gon\u00e7alo M. Topical drugs. In: JohansenJ, MahlerV, LepoittevinJP, et al., eds. Contact Dermatitis. 6th ed. Cham, Switzerland: Springer; 2020:1019\u20131055.","edition":"6"},{"key":"e_1_3_1_34_2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1600-0536.2011.01967.x","article-title":"Immediate and delayed allergic hypersensitivity to corticosteroids: practical guidelines","volume":"66","author":"Baeck M","year":"2012","unstructured":"Baeck M, , Goossens A. Immediate and delayed allergic hypersensitivity to corticosteroids: practical guidelines. Contact Dermatitis, 2012; 66:38\u201345.","journal-title":"Contact Dermatitis"},{"key":"e_1_3_1_35_2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1600-0536.2011.01888.x","article-title":"Patch, prick or intradermal tests to detect delayed hypersensitivity to corticosteroids?","volume":"64","author":"Soria A","unstructured":"Soria A, , Baeck M, , Goossens A, et al. Patch, prick or intradermal tests to detect delayed hypersensitivity to corticosteroids?. Contact Dermatitis 2011;64:313\u2013324.","journal-title":"Contact Dermatitis"},{"key":"e_1_3_1_36_2","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jaip.2015.12.005","article-title":"Bullous nonpigmenting multifocal fixed drug eruption due to pseudoephedrine in a combination drug: clinical and diagnostic observations","volume":"4","author":"Bellini V","year":"2016","unstructured":"Bellini V, , Bianchi L, , Hansel K, et al. Bullous nonpigmenting multifocal fixed drug eruption due to pseudoephedrine in a combination drug: clinical and diagnostic observations. J Allergy Clin Immunol Pract, 2016; 4:542\u2013544.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"e_1_3_1_37_2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1365-2230.2004.01537.x","article-title":"Topical provocation in fixed drug eruption due to metamizol and naproxen","volume":"29","author":"Ozkaya-Bayazit E","year":"2004","unstructured":"Ozkaya-Bayazit E. Topical provocation in fixed drug eruption due to metamizol and naproxen. Clin Exp Dermatol, 2004; 29:419\u2013422.","journal-title":"Clin Exp Dermatol"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1987.tb05879.x"},{"key":"e_1_3_1_39_2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1600-0536.1994.tb01900.x","article-title":"Topical provocation of fixed drug eruption","volume":"31","author":"Alanko K","year":"1994","unstructured":"Alanko K. Topical provocation of fixed drug eruption. A study of 30 patients. Contact Dermatitis, 1994; 31:25\u201327.","journal-title":"A study of 30 patients. Contact Dermatitis"},{"key":"e_1_3_1_40_2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1600-0536.1999.tb06127.x","article-title":"Topical provocation in 27 cases of cotrimoxazole-induced fixed drug eruption","volume":"41","author":"\u00d6zkaya E","year":"1999","unstructured":"\u00d6zkaya E. Topical provocation in 27 cases of cotrimoxazole-induced fixed drug eruption. Contact Dermatitis, 1999; 41:185\u2013189.","journal-title":"Contact Dermatitis"},{"key":"e_1_3_1_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1998.tb05739.x"},{"key":"e_1_3_1_42_2","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/j.1365-2133.1997.tb01584.x","article-title":"Trimethoprim-induced linear fixed drug eruption","volume":"137","author":"\u00d6zkaya-Bayazit E","year":"1997","unstructured":"\u00d6zkaya-Bayazit E, , Baykal C. Trimethoprim-induced linear fixed drug eruption. Br J Dermatol, 1997; 137:1028\u20131029.","journal-title":"Br J Dermatol"},{"key":"e_1_3_1_43_2","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1600-0536.1995.tb02099.x","article-title":"Patch testing in an unusual case of toxic epidermal necrolysis","volume":"33","author":"Klein CE","year":"1995","unstructured":"Klein CE, , Trautmann A, , Zillikens D, et al. Patch testing in an unusual case of toxic epidermal necrolysis. Contact Dermatitis, 1995; 33:448\u2013449.","journal-title":"Contact Dermatitis"},{"key":"e_1_3_1_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2004.12.024"},{"key":"e_1_3_1_45_2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1034\/j.1600-0536.2001.450502.x","article-title":"Relevance of skin tests with drugs in investigating cutaneous adverse drug reactions","volume":"45","author":"Barbaud A","year":"2001","unstructured":"Barbaud A, , Trechot P, , Reichert-Penetrat S, et al. Relevance of skin tests with drugs in investigating cutaneous adverse drug reactions. Contact Dermatitis, 2001; 45:265\u2013268.","journal-title":"Contact Dermatitis"},{"key":"e_1_3_1_46_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0536.2001.450601.x"},{"key":"e_1_3_1_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14492"},{"key":"e_1_3_1_48_2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/cod.12842","article-title":"Patch testing in non-immediate cutaneous adverse drug reactions: value of extemporaneous patch tests","volume":"77","author":"Assier H","year":"2017","unstructured":"Assier H, , Valeyrie-Allanore L, , Gener G, et al. Patch testing in non-immediate cutaneous adverse drug reactions: value of extemporaneous patch tests. Contact Dermatitis, 2017; 77:297\u2013302.","journal-title":"Contact Dermatitis"},{"key":"e_1_3_1_49_2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.0105-1873.2006.00835.x","article-title":"Pitfalls in drug allergy skin testing: false-positive reactions due to (hidden) additives","volume":"54","author":"Grims RH","year":"2006","unstructured":"Grims RH, , Kr\u00e4nke B, , Aberer W. Pitfalls in drug allergy skin testing: false-positive reactions due to (hidden) additives. Contact Dermatitis, 2006; 54:290\u2013294.","journal-title":"Contact Dermatitis"},{"key":"e_1_3_1_50_2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/cod.12269","article-title":"Nonirritant concentrations and amounts of active ingredient in drug patch tests","volume":"71","author":"Brajon D","year":"2014","unstructured":"Brajon D, , Menetre S, , Waton J, et al. Nonirritant concentrations and amounts of active ingredient in drug patch tests. Contact Dermatitis, 2014; 71:170\u2013175.","journal-title":"Contact Dermatitis"},{"key":"e_1_3_1_51_2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2500\/aap.2021.42.200110","article-title":"Evaluation of drug patch tests in children","volume":"42","author":"B\u00fcy\u00fck Yaytokgil \u015e","year":"2021","unstructured":"B\u00fcy\u00fck Yaytokgil \u015e, , G\u00fcvenir H, , K\u00fclha\u015f Cel\u00edk \u0130, et al. Evaluation of drug patch tests in children. Allergy Asthma Proc, 2021; 42:167\u2013174.","journal-title":"Allergy Asthma Proc"},{"key":"e_1_3_1_52_2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/pai.13055","article-title":"Hypersensitivity reactions to antiepileptic drugs in children","volume":"30","author":"Atanaskovi\u0107-Markovi\u0107 M","year":"2019","unstructured":"Atanaskovi\u0107-Markovi\u0107 M, , Jankovi\u0107 J, , Tmu\u0161i\u0107 V, et al. Hypersensitivity reactions to antiepileptic drugs in children. Pediatr Allergy Immunol, 2019; 30:547\u2013552.","journal-title":"Pediatr Allergy Immunol"},{"key":"e_1_3_1_53_2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.0105-1873.2004.00280.x","article-title":"Drug skin tests in cutaneous adverse drug reactions to pristinamycin: 29 cases with a study of cross-reactions between synergistins","volume":"50","author":"Barbaud A","year":"2004","unstructured":"Barbaud A, , Trechot P, , Weber-Muller F, et al. Drug skin tests in cutaneous adverse drug reactions to pristinamycin: 29 cases with a study of cross-reactions between synergistins. Contact Dermatitis, 2004; 50:22\u201326.","journal-title":"Contact Dermatitis"},{"key":"e_1_3_1_54_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1995.tb05066.x"},{"key":"e_1_3_1_55_2","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1016\/j.jaip.2021.02.060","article-title":"DRESS and AGEP reactions to iodinated contrast media: a French case series","volume":"9","author":"Soria A","year":"2021","unstructured":"Soria A, , Amsler E, , Bernier C, et alFISARD group. DRESS and AGEP reactions to iodinated contrast media: a French case series. J Allergy Clin Immunol Pract, 2021; 9:3041\u20133050.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"e_1_3_1_56_2","first-page":"688","article-title":"Results of skin tests to assess drug-induced allergy","volume":"137","author":"Bursztejn A-C","year":"2010","unstructured":"Bursztejn A-C, , Rat A-C, , Tr\u00e9chot P, et al. Results of skin tests to assess drug-induced allergy. Ann Dermatol Venereol, 2010; 137:688\u2013694.","journal-title":"Ann Dermatol Venereol"},{"key":"e_1_3_1_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06429.x"},{"key":"e_1_3_1_58_2","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.jaip.2018.09.014","article-title":"The safety of antibiotic skin testing in severe T-cell-mediated hypersensitivity of immunocompetent and immunocompromised hosts","volume":"7","author":"Trubiano JA","year":"2019","unstructured":"Trubiano JA, , Douglas AP, , Goh M, et al. The safety of antibiotic skin testing in severe T-cell-mediated hypersensitivity of immunocompetent and immunocompromised hosts. J Allergy Clin Immunol Pract, 2019; 7:1341\u20131343.e1.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"e_1_3_1_59_2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/00015550510042859","article-title":"Oral challenge in patients with suspected cutaneous adverse drug reactions: findings in 784 patients during a 25-year-period","volume":"85","author":"Lammintausta K","year":"2005","unstructured":"Lammintausta K, , Kortekangas-Savolainon O. Oral challenge in patients with suspected cutaneous adverse drug reactions: findings in 784 patients during a 25-year-period. Acta Derm Venereol, 2005; 85:491\u2013496.","journal-title":"Acta Derm Venereol"},{"key":"e_1_3_1_60_2","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/j.1365-2133.2008.08975.x","article-title":"Negative predictive value of drug skin tests in investigating cutaneous adverse drug reactions","volume":"160","author":"Waton J","year":"2009","unstructured":"Waton J, , Trlechot P, , Loss-Ayav C, et al. Negative predictive value of drug skin tests in investigating cutaneous adverse drug reactions. Br J Dermatol, 2009; 160:786\u2013794.","journal-title":"Br J Dermatol"},{"key":"e_1_3_1_61_2","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/ced.12214","article-title":"Acute generalized exanthematous pustulosis due to acetazolamide: negative on patch testing and confirmed by delayed-reading intradermal testing","volume":"39","author":"Benamara-Levy M","year":"2014","unstructured":"Benamara-Levy M, , Haccard F, , Jonville Bera AP, et al. Acute generalized exanthematous pustulosis due to acetazolamide: negative on patch testing and confirmed by delayed-reading intradermal testing. Clin Exp Dermatol, 2014; 39:220\u2013222.","journal-title":"Clin Exp Dermatol"},{"key":"e_1_3_1_62_2","doi-asserted-by":"publisher","DOI":"10.1159\/000350939"},{"key":"e_1_3_1_63_2","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/cod.13734","article-title":"Acute generalized exanthematous pustulosis induced by enoxaparin: 2 cases","volume":"84","author":"Assier H","year":"2021","unstructured":"Assier H, , Gener G, , Chosidow O, et al. Acute generalized exanthematous pustulosis induced by enoxaparin: 2 cases. Contact Dermatitis, 2021; 84:280\u2013282.","journal-title":"Contact Dermatitis"},{"key":"e_1_3_1_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.05.042"},{"key":"e_1_3_1_65_2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/jac\/dkm146","article-title":"Aminopenicillin-induced exanthema allows treatment with certain cephalosporins or phenoxymethyl penicillin","volume":"60","author":"Trcka J","year":"2007","unstructured":"Trcka J, , Seitz CS, , Brocker E-B, et al. Aminopenicillin-induced exanthema allows treatment with certain cephalosporins or phenoxymethyl penicillin. J Antimicrob Chemother, 2007; 60:107\u2013111.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_1_66_2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/archderm.1989.01670140151033","article-title":"Patch testing with carbamazepine: reinduction of an exfoliative dermatitis","volume":"125","author":"Vaillant L","year":"1989","unstructured":"Vaillant L, , Camenen I, , Lorette G. Patch testing with carbamazepine: reinduction of an exfoliative dermatitis. Arch Dermatol, 1989; 125:299.","journal-title":"Arch Dermatol"},{"key":"e_1_3_1_67_2","first-page":"983","article-title":"A case of drug-related eruptions due to carbamazepine with a flare from patch testing [in Japanese]","volume":"113","author":"Nitta Y","year":"2003","unstructured":"Nitta Y, , Onouchi H. A case of drug-related eruptions due to carbamazepine with a flare from patch testing [in Japanese]. Jpn J Dermatol, 2003; 113:983\u2013987.","journal-title":"Jpn J Dermatol"},{"key":"e_1_3_1_68_2","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/cod.12956","article-title":"Generalized reactions during skin testing with clindamycin in drug hypersensitivity: a report of 3 cases and review of the literature","volume":"78","author":"Papakonstantinou E","year":"2018","unstructured":"Papakonstantinou E, , M\u00fcller S, , R\u00f6hrbein JH, et al. Generalized reactions during skin testing with clindamycin in drug hypersensitivity: a report of 3 cases and review of the literature. Contact Dermatitis, 2018; 78:274\u2013280.","journal-title":"Contact Dermatitis"},{"key":"e_1_3_1_69_2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1600-0536.1992.tb00132.x","article-title":"Patch testing with clobazam: relapse of generalized drug eruption","volume":"26","author":"Machet L","year":"1992","unstructured":"Machet L, , Vaillant L, , Dardaine V, et al. Patch testing with clobazam: relapse of generalized drug eruption. Contact Dermatitis, 1992; 26:347\u2013348.","journal-title":"Contact Dermatitis"},{"key":"e_1_3_1_70_2","first-page":"359","article-title":"Systemic contact dermatitis due to deflazacort","volume":"43","author":"Garcia-Bravo B","year":"2000","unstructured":"Garcia-Bravo B, , Repiso JB, , Camacho F. Systemic contact dermatitis due to deflazacort. Contact Dermatitis, 2000; 43:359\u2013360.","journal-title":"Contact Dermatitis"},{"key":"e_1_3_1_71_2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1034\/j.1600-0536.2001.045003180.x","article-title":"Generalized reaction after patch testing with metamizol","volume":"45","author":"Gonzalo-Garijo MA","year":"2001","unstructured":"Gonzalo-Garijo MA, , de Arila D, , Rodriguez-Nevado I. Generalized reaction after patch testing with metamizol. Contact Dermatitis, 2001; 45:180.","journal-title":"Contact Dermatitis"},{"key":"e_1_3_1_72_2","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1600-0536.1995.tb02084.x","article-title":"Generalized dermatitis due to mitomycin C patch test","volume":"33","author":"Echechip\u00eda S","year":"1995","unstructured":"Echechip\u00eda S, , Alvarez MJ, , Garc\u00eda BE, et al. Generalized dermatitis due to mitomycin C patch test. Contact Dermatitis, 1995; 33:432.","journal-title":"Contact Dermatitis"},{"key":"e_1_3_1_73_2","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1001\/archderm.139.9.1181","article-title":"A systemic reaction to patch testing for the evaluation of acute generalized exanthematous pustulosis","volume":"139","author":"Mashiah J","year":"2003","unstructured":"Mashiah J, , Brenner S. A systemic reaction to patch testing for the evaluation of acute generalized exanthematous pustulosis. Arch Dermatol, 2003; 139:1181\u20131183.","journal-title":"Arch Dermatol"},{"key":"e_1_3_1_74_2","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1398-9995.1998.tb03986.x","article-title":"Hypersensitivity to piperacillin","volume":"53","author":"Caba\u00f1as R","year":"1998","unstructured":"Caba\u00f1as R, , Mu\u00f1oz L, , L\u00f3pez-Serrano C, et al. Hypersensitivity to piperacillin. Allergy, 1998; 53:819\u2013820.","journal-title":"Allergy"},{"key":"e_1_3_1_75_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1991.tb01657.x"},{"key":"e_1_3_1_76_2","first-page":"312","article-title":"Flare-up reaction of pseudoephedrine baboon syndrome after positive patch test","volume":"42","author":"Sanchez TS","year":"2000","unstructured":"Sanchez TS, , Sanchez-Perez J, , Aragues M, et al. Flare-up reaction of pseudoephedrine baboon syndrome after positive patch test. Contact Dermatitis, 2000; 42:312\u2013313.","journal-title":"Contact Dermatitis"},{"key":"e_1_3_1_77_2","first-page":"230","article-title":"Toxic dermatitis caused by pseudoephedrine: apropos of a case [in French]","volume":"34","author":"Fontaine JF","year":"2002","unstructured":"Fontaine JF, , Lavaud F, , Deslee G, et al. Toxic dermatitis caused by pseudoephedrine: apropos of a case [in French]. Allerg Immunol (Paris), 2002; 34:230\u2013232.","journal-title":"Allerg Immunol (Paris)"},{"key":"e_1_3_1_78_2","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/cod.13733","article-title":"Reactivation of drug reaction with eosinophilia and systemic symptoms with ranitidine patch testing","volume":"84","author":"Teo YX","year":"2021","unstructured":"Teo YX, , Ardern-Jones MR. Reactivation of drug reaction with eosinophilia and systemic symptoms with ranitidine patch testing. Contact Dermatitis, 2021; 84:278\u2013279.","journal-title":"Contact Dermatitis"},{"key":"e_1_3_1_79_2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/cod.12155","article-title":"Severe recurrence of drug rash with eosinophilia and systemic symptoms syndrome secondary to rifampicin patch testing in a human immunodeficiency virus-infected man","volume":"70","author":"Shebe K","year":"2014","unstructured":"Shebe K, , Ngwanya MR, , Gantsho N, et al. Severe recurrence of drug rash with eosinophilia and systemic symptoms syndrome secondary to rifampicin patch testing in a human immunodeficiency virus-infected man. Contact Dermatitis, 2014; 70:125\u2013127.","journal-title":"Contact Dermatitis"},{"key":"e_1_3_1_80_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1999.tb06105.x"},{"key":"e_1_3_1_81_2","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000737"},{"key":"e_1_3_1_82_2","volume-title":"Monographs in Contact Allergy, Volume 3: Topical drugs","author":"De Groot AC","year":"2021","unstructured":"De Groot AC. Monographs in Contact Allergy, Volume 3: Topical drugs. Boca Raton, FL: CRC Press Taylor and Francis Group; 2021. ISBN 978-0-367-23693-9."}],"container-title":["Dermatitis\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1097\/DER.0000000000000839","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1097\/DER.0000000000000839","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1097\/DER.0000000000000839","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:06:13Z","timestamp":1777399573000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1097\/DER.0000000000000839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,1]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2,1]]}},"alternative-id":["10.1097\/DER.0000000000000839"],"URL":"https:\/\/doi.org\/10.1097\/der.0000000000000839","relation":{},"ISSN":["1710-3568","2162-5220"],"issn-type":[{"value":"1710-3568","type":"print"},{"value":"2162-5220","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,1]]}}}